David Mathew Tarlinton

Title: David Mathew Tarlinton: Innovator in Catalytic Antibodies

Introduction

David Mathew Tarlinton is a notable inventor based in Blackburn, Australia. He has made significant contributions to the field of biotechnology, particularly in the development of catalytic antibodies. With a total of 4 patents to his name, Tarlinton's work has implications for therapeutic, diagnostic, and industrial applications.

Latest Patents

Tarlinton's latest patents focus on catalytic antibodies and methods for their production. One of his inventions relates to a growth factor precursor that is utilized to select the production of antigen-specific catalytic antibodies. This process involves B cell activation and proliferation, which is induced by catalytic cleavage products of a target antigen portion of the growth factor precursor. A particularly innovative aspect of his work includes the development of a nucleic acid vaccine that incorporates a molecular adjuvant. Another patent emphasizes a novel method for producing catalytic antibodies, which exploits the products of catalysis to induce B cell mitogenesis. This method links a growth factor capable of inducing B cell mitogenesis to a target antigen, facilitating the generation of catalytic antibodies for various applications.

Career Highlights

Throughout his career, Tarlinton has worked with several organizations, including Amrad Operations Pty Ltd. His expertise in the field has allowed him to contribute to advancements in biotechnology and antibody production.

Collaborations

Tarlinton has collaborated with notable professionals in his field, including Frank Koentgen and Gabriele Maria Suess. These collaborations have further enriched his research and development efforts.

Conclusion

David Mathew Tarlinton is a distinguished inventor whose work in catalytic antibodies has the potential to transform therapeutic and diagnostic practices. His innovative approaches and collaborations continue to influence the field of biotechnology.